/PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that it has entered into an agreement.
27.10.2022 - Year-over-year revenue grows 5%, operating profit up 5%, non-GAAP operating profit up 4% Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) .
San Diego-based medical device company ResMed has announced the acquisition of mementor, a consumer software developer that offers a digital solution for insomnia. The financial terms of the transaction were not disclosed. The acquisition of Leipzig, Germany-based mementor lays the foundation for ResMed to build its digital sleep medicine portfolio in Germany, the company